RUA Life Sciences PLC Change of Nominated Adviser and Broker (0991S)

TIDMRUA

RNS Number : 0991S

RUA Life Sciences PLC

01 November 2023

1 November 2023

Rua Life Sciences plc

("RUA Life Sciences", the "Company" or the "Group")

Change of Nominated Adviser and Broker

RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon(TM), the world leading long-term implantable biostable polyurethane, announces that, following the completion of the all-share merger between Cavendish Securities plc (previously named Cenkos Securities plc) and Cavendish Financial plc (previously named finnCap Group plc), and as a consequence of internal reorganisation within the Cavendish Group, the Company has changed its Nominated Adviser and Broker from Cavendish Securities plc to Cavendish Capital Markets Limited.

For further information contact:

RUA Life Sciences

Bill Brown, Chairman Tel: +44 (0)1294 317073

   Caroline Stretton, Group Managing Director                        Tel: +44 (0)1294 317073 
   Cavendish Capital Markets Limited                                   Tel: +44 (0)20 7220 0500

(Nominated Adviser and Broker)

Giles Balleny / Dan Hodkinson (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon(TM) , the world's leading long-term implantable polyurethane. Whether it is licensing Elast-Eon(TM) , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Contract Manufacture:   End-to-end contract developer and manufacturer 
                              of medical devices and implantable fabric 
                              specialist. 
 RUA Biomaterials:           Licensor of Elast-Eon(TM) polymers to 
                              the medical device industry. 
 RUA Vascular:               Commercialisation of open surgical vascular 
                              grafts and patches 
 RUA Structural Heart:       Development of polymeric leaflet systems 
                              for heart valves.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPDFLFBXFLBFBZ

(END) Dow Jones Newswires

November 01, 2023 13:30 ET (17:30 GMT)

Rua Life Sciences (LSE:RUA)
過去株価チャート
から 4 2024 まで 5 2024